In partnership with

GSK Pharmaceutical Industry Fellowship Program

2018

GSK Pharmaceutical Industry Fellowship Program

2018
Introduction 2

GSK 4

UNC Eshelman School of Pharmacy 6

Fellowships 8-13

- US Medical Affairs 8
- Global Regulatory Affairs 10
- Pharmaceutical Outcomes Research 12

UNC GSK Fellowship Alumni 14

Application and Eligibility 15

Cover image

We aim to achieve industry-leading growth by investing effectively in our business, developing our people, and striving for innovation.

We commit to scientific and technical excellence by developing new products that meet the needs of patients, payers, and consumers.
Introduction

The fellowship programs, in partnership with UNC Eshelman School of Pharmacy and GSK, aim to develop pharmaceutical industry professionals to become successful leaders and innovators.

Today there are millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions of people who suffer from everyday ailments. We want to change this. That’s why we are harnessing our scientific and technical know-how, our talented people, our partnerships, and our global reach to develop and manufacture healthcare products for people who need them.

Our mission is to improve the quality of human life by enabling people to do more, feel better, and live longer.

Fellowships offered by GSK in partnership with UNC Eshelman School of Pharmacy include:

- **US Medical Affairs** (PharmD or PhD)
- **Global Regulatory Affairs** (PharmD, PhD, or MD)
- **Pharmaceutical Outcomes Research** (PharmD, PhD, or MD)

GSK

We are one of the largest global pharmaceutical companies

Today there are millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions of people who suffer from everyday ailments. We want to change this. That’s why we are harnessing our scientific and technical know-how, our talented people, our partnerships, and our global reach to develop and manufacture healthcare products for people who need them.

Our mission is to improve the quality of human life by enabling people to do more, feel better, and live longer.

Our strategy

Bring quality, needed healthcare products to as many people as possible, with our scientific and technical know-how and talented people.
Who we are
We have 3 global businesses that research, develop, and manufacture innovative pharmaceutical medicines, vaccines, and consumer healthcare products. Our goal is to be one of the world’s most innovative, best performing, and trusted healthcare companies.

What we do
We aim to bring differentiated, high-quality, and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals
Our Pharmaceuticals business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory, HIV, oncology, and immunoinflammation; with discovery research exploring these and other areas.

Sales turnover 2017
£17.3bn
Top 3 selling drivers 2017
Triumeq/Tivicay HIV
Sere tide/Advair Respiratory
Ellipta portfolio Respiratory

Vaccines
Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We deliver over two million vaccine doses per day to people living in over 160 countries.

Sales turnover 2017
£5.2bn
Top 3 selling vaccines 2017
Meningitis Paediatric and adult
Infanrix/Infanrix Pediarix Paediatric
Hepatitis Paediatric and adult

Consumer Healthcare
Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the oral health, pain relief, respiratory, nutrition/gastrointestinal, and skin health categories.

Sales turnover 2017
£7.8bn
Top 3 selling brands 2017
Sensodyne Oral health
Voltaren Pain relief
Panadol Pain relief

Innovation
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£3.9bn R&D investment in 2017
£6.7bn new product sales in Vaccines and Pharmaceuticals in 2017
3 major launches in 2017 – Shingrix, a vaccine for shingles, Trelegy Ellipta for COPD and Juluca for HIV

Performance
We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

£30.2bn total turnover in 2017
£8.6bn adjusted operating profit in 2017
£3.4bn free cash flow in 2017
13% dividends declared in 2017

Trust
We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.

8bn packs/doses of healthcare products produced in 2017
85% of employees proud to work at GSK
£262m donated to local communities through product donations, time and cash in 2017
1st in the Access to Medicines Index all 5 times since its launch in 2008

Our values and expectations
Our values and expectations are at the heart of everything we do and form an important part of our culture.

Our values
• Patient focus
• Transparency
• Respect
• Integrity

Our expectations
• Courage
• Accountability
• Development
• Teamwork

Why we do it
To help people do more, feel better, live longer.
UNC PARTNERSHIP

The UNC Eshelman School of Pharmacy, ranked as the #1 pharmacy school in the nation by the US News and World Report 2016, is a nationally recognized leader in progressive pharmaceutical care practice, education, and research.

CHAPEL HILL
The Eshelman School of Pharmacy is part of the University of North Carolina at Chapel Hill, a major research university with a large academic medical center. The School of Pharmacy has specialized research centers pursuing advancements in drug delivery, nanotechnology cancer treatment, pharmacogenomics, and medication optimization.

The Chapel Hill campus is close to the RTP business region, and several large health systems. It offers a rich blend of culture, entertainment, recreation, fine dining, and some of the best college basketball action in the country.

RESEARCH TRIANGLE PARK (RTP)
UNC anchors one corner of North Carolina’s famed RTP which hosts an abundance of pharmaceutical, biotechnology, and healthcare companies. This environment offers opportunities for collaboration in research, education, and patient care with partners in academia, industry, and healthcare.

RTP is the largest GSK commercial site that operates in the US and houses critical roles in pharmaceuticals, corporate, and manufacturing functions, as well as Research and Development (R&D) and ViiV Healthcare.

US Medical Affairs and Pharmaceutical Outcomes Research fellows gain pharmaceutical industry experience during the second year of the fellowship program at RTP. Global Regulatory Affairs fellows spend 2-3 days per week at RTP for the first 6 months of the fellowship.

UPPER PROVIDENCE (UP) / COLLEGEVILLE
The Upper Providence GSK site, which is the US R&D Hub, is named for its location in Upper Providence Township, Montgomery County, Pennsylvania. It is approximately 30 miles northwest of Center City Philadelphia and approximately 35 miles from Philadelphia International Airport.

Global Regulatory Affairs fellows relocate to UP or have the opportunity to stay in RTP after the completion of the first 6 months of the fellowship program.

"Each year, for more than three decades, we have an incredible group of fellows, who make a significant contribution to the legacy of our program. These fellows are a reflection of UNC and GSK’s strong long-standing commitment to train and develop the newest generation of pharmaceutical industry professionals."

Robert Dupuis, PharmD, FCCP

"Year after year, I am in awe of our fellows’ initiative and innovation and the unique hands-on learning opportunities afforded to them by the University and GSK."

Jo Ellen Rodgers, PharmD, BCPS, FCCP
US Medical Affairs fellowship

The US Medical Affairs fellowship at GSK provides the practical training and experience needed to successfully obtain a position in the pharmaceutical industry, academia, clinical practice, or Contract Research Organizations.

Fellows will work in a cross-functional matrix team which consists of the US Medical Affairs Lead, therapy area scientific/medical directors, global medical affairs, global clinical safety and pharmacovigilance, regulatory affairs, legal, health outcomes, research and development, and commercial.

Program structure

Year one

At UNC Eshelman School of Pharmacy, fellows will have the opportunity to

• Review the principles of clinical research, such as Good Clinical Practice (GCP) and gain an understanding of the wellbeing of study subjects, data collection, analysis, and safety reporting
• Apply clinical design strategies, evaluate research designs and study reports, and utilize biostatistical tests
• Develop protocols, recruit and monitor subjects, collect and analyze data, and prepare an academic manuscript

Year two

At GSK within US Medical Affairs, fellows will have the opportunity to

• Understand the decision-making process that healthcare providers and payers follow for drug utilization
• Contribute to the development and execution of US Medical Affairs plans and integrate the voice of the customer including, providers, payers, patients, into a medical affairs strategy
• Gain clinical knowledge and product expertise in a therapeutic area

"The partnership with UNC provides fellows the opportunity to build a solid drug development foundation from a variety of academic learnings and apply acquired knowledge at GSK. Fellows gain an appreciation of the value of scientific engagement between GSK and external communities and make significant contributions that can have a positive impact on patient lives."

Shelly Lener, PharmD

Fellowship objectives

• Work closely with US Medical Affairs Leads and Accountable Medical Leads to execute tactics that support the overall medical strategy
• Understand principles of clinical research, apply clinical trial design strategies, and collect and analyze data
• Conduct strategic reviews of the medical literature and the competitive environment to identify data and educational gaps to enhance patient care
• Contribute to US scientific engagement between GSK and external communities to advance the understanding of disease treatment and management
• Participate in the medical review of promotional materials and communicate scientific information to internal and field based colleagues
• Support launch preparations for new medicines and/or new indications or label extensions

Program Director

Shelly Lener, PharmD
US Medical Affairs Leader, Scientific Director, US Medical Affairs, GSK

Preceptors

Bryant Tran, PharmD, MS, MBA
Scientific Director, US Medical Affairs, GSK

Laura Sutton, PharmD
Therapeutic Area, Scientific Director, CMO Medical Affairs, GSK

Fellows

Kristin Moody, PharmD
Second Year Fellow
UNC Eshelman School of Pharmacy

Hitesh Patel, PharmD
Second Year Fellow
UNC Eshelman School of Pharmacy

Lauren Hothem, PharmD
First Year Fellow
UNC Eshelman School of Pharmacy

Alexis Kahina Williams, PharmD
First Year Fellow
UNC Eshelman School of Pharmacy
Global Regulatory Affairs fellowship

The Global Regulatory Affairs (GRA) fellowship provides practical training and experience in regulatory affairs to help fellows gain expertise in regulatory requirements and strategy pertinent to drug development.

Through a combination of academic and industry training, fellows will develop an in-depth understanding of regulatory affairs and the drug development process from pre-clinical to post-marketing stages. Fellows will establish a strong foundation to obtain a successful career within the pharmaceutical industry, academia, Food and Drug Administration (FDA), or Contract Research Organizations.

Fellowship objectives

- Partake in didactic courses, such as Drug Development, Clinical Trial Design, Leadership, and the US Regulatory Affairs Certification (RAC)
- Apply principles of pharmaceutical product development and develop regulatory strategy by using and interpreting regulations and guidelines
- Provide support to the life-cycle management activities pre and post approval for drug and biologic products and gain an understanding of the principles of agency review processes
- Review study protocols, informed consent forms, Institutional Review Board (IRB) applications, and safety assessment reports
- Understand the various facets that exist within GRA including labeling, advertising and promotion, regulatory intelligence and strategy, chemistry manufacturing and controls, and non-clinical regulatory
- Gain an understanding of early and late phase clinical development and comprehend requirements of regulatory submissions

First 6 months

During the first six months of the fellowship, fellows spend 2-3 days a week at UNC and have the opportunity to

- Gain exposure in the Clinical Trial Research Center (CTRC), working alongside the Institute for Global Health and Infectious Diseases and UNC Lineberger Comprehensive Cancer Center
- Obtain an understanding of clinical trial research and regulatory documentation for IRB submission
- Participate in academic courses in experimental design and clinical research, obtain a Teaching Certification with UNC Eshelman School of Pharmacy, and complete the RAC course

“Fellows are given the opportunity to utilize the knowledge and leadership skills they have obtained at UNC and gain hands-on experience in the pharmaceutical industry at GSK. The program also assists in identifying and developing emerging talent to potentially support the future GSK business. On behalf of GRA, we very much look forward to working with the fellows over the coming years!”

Mark DeSlatto
Vice President, Global Regulatory Affairs,
Therapeutic Group,
GSK

Last 16-18 months

Fellows will spend sixteen to eighteen months full-time in GRA at GSK and have the opportunity to

- Gain hands-on experience across all phases of drug development
- Complete an optional rotational opportunity at the FDA
- Develop valuable regulatory strategic skills and function as an effective project team member
- Prepare regulatory interaction documents and submission packages and interact with regulatory agencies to guide product development

“Fellows are given the opportunity to utilize the knowledge and leadership skills they have obtained at UNC and gain hands-on experience in the pharmaceutical industry at GSK. The program also assists in identifying and developing emerging talent to potentially support the future GSK business. On behalf of GRA, we very much look forward to working with the fellows over the coming years!”

Mark DeSlatto
Vice President, Global Regulatory Affairs,
Therapeutic Group,
GSK

Sponsor
Mark DeSlatto
Vice President, Global Regulatory Affairs,
Therapeutic Group,
GSK

Program Director
Kevin Flagerfeld, BSPharm
Senior Director, OCRO Operations, R&D Chief Regulatory Office, GSK

Program Preceptor
Elvis Osei Tutu, PharmD, RAC
Manager, Global Regulatory Affairs, Therapeutic Groups, GSK

Fellows

Sara Angione, PharmD, MS
Second Year Fellow
Fairleigh Dickinson University School of Pharmacy & Health Sciences

Kristina Vishnevetskaya, PharmD
Second Year Fellow
Rutgers University

Ariana Ayon Verduzco, PharmD
First Year Fellow
Keck Graduate Institute School of Pharmacy

Kwadwo Yeboah, PharmD
First Year Fellow
Purdue University
The Pharmaceutical Outcomes Research fellowship is a partnership between the Division of Pharmaceutical Outcomes and Policy (DPOP) at the UNC Eshelman School of Pharmacy and the US Values, Evidence, and Outcomes group at GSK. The partnership allows fellows to develop a strong methodological background in outcomes research and apply knowledge to industry and academic based projects.

Fellowship objectives

- Generate real world evidence, model cost-effectiveness of medications, and understand the impact of how policies affect medication use and health outcomes
- Understand the multi-level factors affecting health, including patients, families, physician clinical practice, the US healthcare system, and Government policy
- Learn to develop health outcomes strategies and studies in the context of academic and industry settings to provide evidence and solutions using advanced pharmacoepidemiology and pharmacoeconomics methods
- Obtain the knowledge, skills, and resources needed effectively work cross-functionally within a matrix environment

- Gain an understanding of the US payer market and how use of health outcomes data can be used to incentivize value-based care and in comparative effectiveness research
- Develop the ability to choose the appropriate study design and statistical methodology to generate scientific evidence that is applicable in diverse settings

Program structure

Year one
At UNC, fellows will spend approximately 80% of their time supplementing their didactic education and have the opportunity to

- Learn the science of health services research and apply knowledge to research projects at UNC and GSK
- Develop leadership, communication, and strategic thinking skills while working within research teams
- Partake in didactic courses related to research methods, statistics, pharmacoepidemiology, pharmaceutical policy, and/or pharmacoeconomics
- Pursue graduate level coursework that may be applied towards degree requirements for a UNC graduate program
- Design and conduct various research projects under the mentorship of faculty and preceptors

Year two
At GSK, fellows spend 80% of their time in the US Values, Evidence, and Outcomes department and have the opportunity to

- Apply health outcomes research methodology and engage in strategy discussions across various groups within US Medical Affairs
- Improve competency in generation of health outcomes evidence related to US marketed pharmaceuticals and therapy areas
- Understand the US payer environment, communication of evidence to external and internal customers, and study conduct
- Enroll in didactic courses to further enhance an understanding of outcomes research and partake in research projects at UNC and GSK

Fellows

- Daniel Grabke, PharmD
  Second Year Fellow
  University of Illinois-Chicago

- Benjamin Wu, PharmD
  First Year Fellow
  University of Maryland School of Pharmacy

- Joeh Nguyen, MPH
  Predoctoral fellow
  Brown University School of Public Health

Sponsor

Richard H Stanford, PharmD, MS
Senior Director, US Customer Engagement Value, Evidence, and Outcomes, GSK

Program Directors

- Jennifer Elston Lafata, PhD
  Professor, Vice Department Chair, Division of Pharmaceutical Outcomes and Policy, UNC

- Richard H Stanford, PharmD, MS
  Senior Director, US Customer Engagement Value, Evidence, and Outcomes, GSK

‘Our partnership with the UNC Eshelman School of Pharmacy allows for a unique synergistic learning environment where fellows have the opportunity to apply real-time learnings to a real-life research setting and ultimately to a career in health services research.’

Richard H Stanford, PharmD, M.S
Employed at GSK

Keith Pappa
Director, Clinical Development, Chief Scientific and Medical Office, Viiv Clinical Research & Drug Development fellow 1986-1988

Karol LaCroix
Team Leader, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1989-1990

Linda Clayton
Director, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1990-1992

Lynn Henson
Senior Director, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1993-1995

Katy Moore
Senior Director, Therapeutic Group, Global Regulatory Affairs, GSK Clinical Research & Drug Development fellow 1994-1996

Patrick Wire
Senior Director, Therapeutic Group, Global Regulatory Affairs, GSK Clinical Research & Drug Development fellow 1995-1997

Melissa Ellis
Director, SERM, Central Safety Department, GSK Clinical Research & Drug Development fellow 1994-1996

Rob Kustra

Amy Meadowcroft
Director, Clinical Development, Medicine Delivery, GSK Clinical Research & Drug Development fellow 1996-1998

Sarah Roberts
Manager, Global Regulatory Affairs, Labeling, GSK Clinical Research & Drug Development fellow 1999-2000

Michael Watkins

Susan Ford
Director, Clinical Pharmacology, GSK Pharmacokinetics & Pharmacodynamics fellow 2000-2002

Trina Clark
Director, National Health Outcomes Liaison, CMO Medical Affairs, GSK Global Health Outcomes fellow 2001-2003

Michael Lim
Director, EPCS, Global Oncology Franchise, GSK Drug Development fellow 2004-2006

Lakshmi Vasist
Manager, Clinical Pharmacology, GSK Pharmacokinetics & Pharmacodynamics fellow 2004-2006

Justin Kotef
Director, Scientific Communications, Strategy & Medical Information, Viiv Clinical Research & Drug Development fellow 2009-2011

Bryant Tran
Scientific Director, US Medical Affairs, GSK Clinical Research & Drug Development fellow 2009-2011

Elizabeth Blair
Director, Clinical Development, Scientific Medical Office, Viiv Clinical Research & Drug Development fellow 2012-2014

Pranav Bhatt
Manager, Clinical Development, Medicine Delivery, GSK Clinical Research & Drug Development fellow 2012-2014

Christine Trezza
Manager, Clinical Development, Medicine Delivery, GSK Clinical Research & Drug Development fellow 2013-2016

Michael Bogart

Jennifer Kim Cremer
Manager, Clinical Development, Infectious Disease, GSK Clinical Research & Drug Development fellow 2014-2016

Elizaveta Budko
Manager, Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2014-2016

Elvis Osei Tutu
Manager, Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2014-2016

Brittany Dustman
Manager, Global Regulatory Affairs Therapeutic Groups, GSK Global Regulatory Affairs fellow 2016-2018

Shivam Patel
Manager, Oncology Therapeutic Group, Global Regulatory Affairs, GSK Global Regulatory Affairs fellow 2016-2018

Pranav Paka
Manager, Global Medical Affairs Oncology, GSK Medical Affairs fellow 2016-2018

EMPLOYED AT UNC

Denise Rhoney
Associate Dean for Curricular Innovation, PACE, UNC Eshelman School of Pharmacy Clinical Research & Drug Development fellow 1993-1995

Craig R. Lee
Associate Professor of Pharmacy, DPET, UNC Eshelman School of Pharmacy Clinical Research & Drug Development fellow 2000-2002
Interested applicants should submit a letter of interest, curriculum vitae, official transcript, and three letters of recommendation electronically by January 1, 2019. Early applications are encouraged. Questions or submissions should be sent to the following email address: UNC-DPOP@email.unc.edu

The UNC Eshelman School of Pharmacy and GSK Pharmaceutical Industry Fellowships commence in July 2019. Applicants are highly recommended to attend ASHP Midyear Clinical Meeting/PPS. Interviews are prearranged and are selected on a competitive basis.

**Application and Eligibility**

The UNC Eshelman School of Pharmacy and GSK Pharmaceutical Industry Fellowships commence in July 2019. Applicants are highly recommended to attend ASHP Midyear Clinical Meeting/PPS. Interviews are prearranged and are selected on a competitive basis.

**Pharmaceutical Outcomes Research**

Interested applicants should submit a letter of interest, curriculum vitae, official transcript, and three letters of recommendation electronically by January 1, 2019. Early applications are encouraged. Questions or submissions should be sent to the following email address: UNC-DPOP@email.unc.edu

Visit http://pharmacydpetfellowships.web.unc.edu/ for instructions on submitting an application.

**US Medical Affairs and Global Regulatory Affairs**

The application deadline for early consideration is November 15, 2018. The final deadline to apply is January 1, 2019. Early applications are highly encouraged.